Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study
JMIR Cancer · 2025
DOI: 10.2196/65118 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift JMIR Cancer, 2025. Verfasst von Phyu Sin Aye und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Gefitinib, Erlotinib Hydrochloride, Lung Neoplasms. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Health care system–wide outcomes from routine treatment with erlotinib and gefitinib are incompletely understood.
Objective
The aim of the study is to describe the effectiveness of erlotinib and gefitinib during the first decade of their routine use for treating advanced epidermal growth factor receptor ( EGFR ) mutation-positive nonsquamous non–small cell lung cancer in the entire cohort of patients treated in Aotearoa New Zealand.
Methods
Patients were identified, and data collated from national pharmaceutical dispensing, cancer registration, and mortality registration electronic databases by deterministic data linkage using National Health Index numbers. Time-to-treatment discontinuation and overall survival were measured from the date of first dispensing of erlotinib or gefitinib and analyzed by Kaplan-Meier curves. Associations of treatment outcomes with baseline factors were evaluated using univariable and multivariable Cox regressions.
Results
Overall, 752 patients were included who started treatment with erlotinib (n=418) or gefitinib (n=334) before October 2020. Median time-to-treatment discontinuation was 11.6 (95% CI 10.8‐12.4) months, and median overall survival was 20.1 (95% CI 18.1‐21.6) months. Shorter time-to-treatment discontinuation was independently associated with high socioeconomic deprivation (hazard ratio [HR] 1.3, 95% CI 1.1‐1.5 compared to the New Zealand Index of Deprivation 1‐4 group), EGFR L858R mutations (HR 1.3, 95% CI 1.1‐1.6 compared to exon 19 deletion), and distant disease at cancer diagnosis (HR 1.4, 95% CI 1.2‐1.7 compared to localized or regional disease). The same factors were independently associated with shorter overall survival. Outcome estimates and predictors remained unchanged in sensitivity analyses.
Conclusions
Outcomes from routine treatment with erlotinib and gefitinib in New Zealand patients with advanced EGFR -mutant nonsquamous non–small cell lung cancer are comparable with those reported in randomized trials and other health care system–wide retrospective cohort studies. Socioeconomic status, EGFR mutation subtype, and disease extent at cancer diagnosis were independent predictors of treatment outcomes in that setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.
- School of Pharmacy, University of Auckland, Auckland, New Zealand.
- Te Aka Mātauranga Matepukupuku Centre for Cancer Research, University of Auckland, Auckland, New Zealand.
- Department of Medical Oncology, Te Pūriri o Te Ora Regional Cancer and Blood Service, Te Whatu Ora Health New Zealand, Auckland City Hospital, Auckland, New Zealand.
- Department of Medical Oncology, Te Whatu Ora Health New Zealand Te Pae Hauuora o Ruahine o Tararua, Palmerston North Hospital, Palmerston North, New Zealand.
- Wellington Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital, Coast and Hutt Valley, Wellington Hospital, Wellington, New Zealand.
ORCID-Profile: Phyu Sin Aye, Joanne Barnes, George Laking, Laird Cameron, Malcolm Anderson, Brendan Luey, Stephen Delany, Dean Harris, Blair McLaren, Elliott Brenman, Jayden Wong, Ross Lawrenson, Michael Arendse, Sandar Tin Tin, Mark Elwood, Philip Hope, Mark James McKeage
Zitieren
APA
Aye, P. S., Barnes, J., Laking, G., Cameron, L., Anderson, M., Luey, B., Delany, S., Harris, D., McLaren, B., Brenman, E., Wong, J., Lawrenson, R., Arendse, M., Tin Tin, S., Elwood, M., Hope, P., & McKeage, M. J. (2025). Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study. JMIR Cancer. https://doi.org/10.2196/65118
Vancouver
Aye PS, Barnes J, Laking G, Cameron L, Anderson M, Luey B, et al. Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study. JMIR Cancer. 2025. doi:10.2196/65118
BibTeX
@article{Aye2025,
author = {Aye, Phyu Sin and Barnes, Joanne and Laking, George and Cameron, Laird and Anderson, Malcolm and Luey, Brendan and Delany, Stephen and Harris, Dean and McLaren, Blair and Brenman, Elliott and Wong, Jayden and Lawrenson, Ross and Arendse, Michael and Tin Tin, Sandar and Elwood, Mark and Hope, Philip and McKeage, Mark James},
title = {Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study},
journal = {JMIR Cancer},
year = {2025},
doi = {10.2196/65118}
}
EUVIMED